Plasma Cell Myeloma News and Research

RSS
FDA grants accelerated approval to new treatment for refractory multiple myeloma

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Revlimid clinical data in newly diagnosed multiple myeloma presented

Revlimid clinical data in newly diagnosed multiple myeloma presented